The Faculty of Pharmacy, Mahidol University supported help Sri Lanka graduate student estimated the economic cost of smoking and smokeless tobacco (ST) related to cancers in Sri Lanka. Cancer has a high mortality rate and morbidity burden in Sri Lanka. The study assessed the prevalence-based cost of illness calculated according to the guidelines of the WHO (2011). The direct costs are costs of curative care (costs of inward patients and outpatient care borne by the state and out of pocket expenditure by households) for tobacco-related cancers, weighted by the attributable fractions for these cancers. Indirect costs are lost earnings due to mortality and morbidity (absenteeism of both patient and carers resulting from seeking care and recuperation). Data were obtained from the Registrar General's Department, National Cancer Registry, Department of Census and Statistics and the Central Bank of Sri Lanka. Household and systemic costs and relative risks were extracted from research studies. Oncologists (working in both public and private sectors), other clinical specialists, medical administrators and economists were consulted during the estimation and validation processes. Study results showed that the total economic cost of tobacco-related cancers for Sri Lanka in 2015 was estimated to be US$121.2 million. The direct cost of smoking and ST-related cancers was US$42.1 million, which was 35% of the total cost, while the indirect cost was US$79.1 million, which was 65% of the total cost. Based on this work, it is clear that burden of tobacco smoking and ST-related cancers as reflected in these economic costs is enormous: affecting the healthcare system and country's economy. Policymakers should take note of this burden and address tobacco consumption control as a priority.
สงวนลิขสิทธิ์ © 2563
ออกแบบและพัฒนาโดยงานเทคโนโลยีสารสนเทศฯ คณะเภสัชศาสตร์ ม.มหิดล